Table 2 Baseline clinical characteristics by initiated drug class in CANTATA D and D2 randomised trials, and Clinical Practice Research Datalink (UK primary care data). Data are mean (SD) unless stated
| Â | Derivation set: CANTATA D and D2 trials | Validation set: Clinical Practice Research Datalink | ||
|---|---|---|---|---|
|  | SGLT2-inhibitor (n = 715) [Canagliflozin 300 mg] | DPP4-inhibitor (n = 713) [Sitagliptin 100 mg] | SGLT2-inhibitor (n = 11,682) [Any class] | DPP4-inhibitor (n = 7,059) [Any class] |
Trial (n %) | ||||
 CANTATA-D | 355 (49.7) | 356 (49.9) | NA | NA |
 CANTATA-D2 | 360 (50.3) | 357 (50.1) | NA | NA |
Age (years) | 55.9 (9.4) | 56.0 (9.4) | 59.9 (9.1) | 64.0 (10.8) |
Sex (n %) | ||||
 Female | 355 (49.7) | 339 (47.5) | 4,393 (37.6) | 2,593 (36.7) |
 Male | 360 (50.3) | 374 (52.5) | 7,289 (62.4) | 4,466 (63.3) |
HbA1c (mmol/mol) | 63.9 (9.9) | 63.9 (9.9) | 76.8 (14.2) | 72.4 (13.2) |
BMI (kg/m2) | 31.5 (6.6) | 31.9 (6.5) | 34.4 (6.6) | 32.2 (6.4) |
eGFR (mL/min/1.3 m2) | 88.5 (18.2) | 88.2 (19.5) | 88.8 (14.4) | 82.9 (17.2) |
HDL-c (mmol/L) | 1.2 (0.3) | 1.2 (0.3) | 1.1 (0.3) | 1.2 (0.3) |
LDL-c (mmol/L) | 2.7 (0.9) | 2.7 (0.9) | 2.4 (1.0) | 2.3 (0.9) |
Triglycerides (mmol/L) | 2.1 (1.4) | 1.9 (1.2) | 2.3 (1.4) | 2.1 (1.3) |
ALT (IU/L) | 28.8 (18.5) | 28.2 (14.7) | 36.5 (44.2) | 33.9 (56.9) |
Albumin (g/L) | 41.0 (3.3) | 41.0 (3.3) | 42.4 (4.0) | 42.4 (3.9) |
Bilirubin (µmol/L) | 8.3 (4.0) | 8.0 (0.9) | 9.8 (5.0) | 10.0 (5.1) |
Number of concurrent glucose-lowering drugs (n %) | ||||
 0 | 0 | 0 | 187 (2.6) | 665 (5.7) |
 1 | 355 (49.7) | 356 (49.9) | 2818 (39.9) | 6947 (59.5) |
 2 | 360 (50.3) | 357 (50.1) | 3268 (46.3) | 3914 (33.5) |
 3 | 0 | 0 | 786 (11.1) | 156 (1.3) |